<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03023319</url>
  </required_header>
  <id_info>
    <org_study_id>EXP-16-01</org_study_id>
    <nct_id>NCT03023319</nct_id>
  </id_info>
  <brief_title>Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors</brief_title>
  <official_title>Phase I Study of the Non-receptor Kinase Inhibitor Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nagla Abdel Karim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Augusta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the maximum-tolerated dose (MTD) for oral bosutinib when used in
      combination with pemetrexed. The MTD is the highest dose of bosutinib with pemetrexed that
      can be given without causing severe side effects. This study will also test the safety of
      this combination and see what effects (good or bad) it has on participants and their cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2019</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity of the combination of bosutinib and pemetrexed</measure>
    <time_frame>21 days</time_frame>
    <description>CTCAE Grade 3 or 4 non‚Äêhematologic toxicities other than alopecia, nausea and vomiting.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose of the combination of bosutinib and pemetrexed</measure>
    <time_frame>completion of dose escalation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events of the combination of bosutinib and pemetrexed</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor response rate</measure>
    <time_frame>6 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>6 and 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Mesothelioma</condition>
  <condition>Bladder Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Peritoneal Cancer</condition>
  <condition>Thymoma</condition>
  <condition>Thymus Cancer</condition>
  <condition>Uterine Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Bosutinib and Pemetrexed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bosutinib and pemetrexed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosutinib</intervention_name>
    <description>100mg daily for 4 cycles (21 days per cycle)</description>
    <arm_group_label>Bosutinib and Pemetrexed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>500 mg/m2 every 21 days for 4 cycles</description>
    <arm_group_label>Bosutinib and Pemetrexed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically or cytologically proven advanced, metastatic non-squamous non-small
             cell lung cancer, pleural malignant mesothelioma, bladder or urethral cancer, ovarian
             cancer, primary peritoneal cancer, thymoma and thymic cancer and uterine cervical
             cancer.

          -  Measurable disease

          -  Life expectancy of greater than 3 months.

          -  Ability to take folic acid, vitamin B12, and dexamethasone according to protocol.

        Exclusion Criteria:

        - Untreated or symptomatic brain metastases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nagla Karim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Augusta University Georgia Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kelly Jenkins, RN, MSN</last_name>
    <phone>706-721-1206</phone>
    <email>kejenkins@augusta.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ashlyn Stevenson, RN, BSN</last_name>
    <phone>706-721-0660</phone>
    <email>asstevenson@augusta.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Augusta University Georgia Cancer Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Jenkins, MSN, RN</last_name>
      <phone>706-721-1206</phone>
      <email>kejenkins@augusta.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ashlyn Stevenson, BSN, RN</last_name>
      <phone>706-721-0660</phone>
      <email>asstevenson@augusta.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nagla A Karim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 13, 2017</study_first_submitted>
  <study_first_submitted_qc>January 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2017</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Augusta University</investigator_affiliation>
    <investigator_full_name>Nagla Abdel Karim</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Thymoma</mesh_term>
    <mesh_term>Thymus Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

